This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
The Zacks Analyst Blog Highlights Amphastar Pharmaceuticals, Journey Medical, Centessa Pharmaceuticals and Aquestive Therapeutics
by Zacks Equity Research
Amphastar Pharmaceuticals, Journey Medical, Centessa Pharmaceuticals and Aquestive Therapeutics are part of the Zacks top Analyst Blog.
What Awaits These 4 Drug Stocks That More Than Doubled in 2023?
by Ahan Chakraborty
Here are four drug, biotech stocks, AMPH, DERM, CNTA & AQST, which have more than doubled in 2023 with room for further growth in 2024.
argenx (ARGX) Tanks on Top-Line Data From Pemphigus Study
by Zacks Equity Research
argenx's (ARGX) phase III ADDRESS study, evaluating efgartigimod subcutaneous for treating pemphigus, fails to meet primary and secondary endpoints. Stock falls.
Anavex (AVXL) Rises as CHMP Deems Blarcamesine Eligible for MAA
by Zacks Equity Research
The CHMP agrees that Anavex's (AVXL) blarcamesine for Alzheimer's disease is eligible for submission for a Union Marketing Authorisation in the EU. Shares rise.
4 Drug Stocks Rising More Than 40% in 2023 With Room to Grow
by Kinjel Shah
Novo Nordisk (NVO), Journey Medical Corporation (DERM), Lyra Therapeutics (LYRA) and Fusion Pharmaceuticals (FUSN) have returned 40% or higher year to date and have room for more growth in 2024.
Invivyd (IVVD) Surges on Positive Data From COVID-19 Study
by Zacks Equity Research
Invivyd (IVVD) reports positive initial data from the phase III CANOPY study on VYD222 for the prevention of symptomatic COVID-19. Stock shoots up on the news.
Arcutis (ARQT) Up on FDA Nod for Zoryve in Seborrheic Dermatitis
by Zacks Equity Research
The FDA approves Arcutis' (ARQT) NDA for Zoryve topical foam 0.3% for treating seborrheic dermatitis in individuals nine years of age and above.
Apellis (APLS) Falls on Europe Update for Pegcetacoplan in GA
by Zacks Equity Research
The CHMP may adopt a negative opinion on Apellis' (APLS) intravitreal pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration in the EU. Stock declines.
Amgen's (AMGN) Tarlatamab BLA Gets FDA Priority Tag for SCLC
by Zacks Equity Research
Amgen's (AMGN) BLA for tarlatamab to treat advanced small cell lung cancer gets FDA's priority review. A decision is expected on Jun 12, 2024.
Candel (CADL) Rises on FDA's Fast Track Status for CAN-2409
by Zacks Equity Research
The FDA gives Fast Track designation to Candel's (CADL) lead candidate, CAN-2409 plus prodrug (valacyclovir), for the treatment of patients with pancreatic cancer.
Is it a Good Idea to Buy Journey Medical (DERM) Stock Now?
by Zacks Equity Research
Here, we discuss some reasons why investing in Journey Medical (DERM) stock now may turn out to be a prudent move.
GSK's Jemperli Gets EU Nod for Endometrial Cancer Expanded Use
by Zacks Equity Research
GSK's Jemperli combo receives the European Commission's marketing authorization as a frontline treatment for certain types of primary advanced/recurrent endometrial cancer.
Zacks Industry Outlook Highlights Aurinia Pharmaceuticals, Alpine Immune Sciences, Lyra Therapeutics, Harpoon Therapeutics and Journey Medical
by Zacks Equity Research
Aurinia Pharmaceuticals, Alpine Immune Sciences, Lyra Therapeutics, Harpoon Therapeutics and Journey Medical are part of the Zacks Industry Outlook article.
Pfizer's (PFE) Multiple Myeloma Drug Elrexfio Gets Nod in EU
by Zacks Equity Research
Pfizer's (PFE) targeted immunotherapy, Elrexfio, for treating heavily pretreated adults with relapsed/refractory multiple myeloma gets EC's conditional marketing authorization.
Merck's (MRK) Keytruda, Lenvima Endometrial Cancer Study Fails
by Zacks Equity Research
The combination of Merck's (MRK) Keytruda and Eisai's Lenvima for the first-line treatment of advanced/recurrent endometrial carcinoma fails to meet dual primary endpoints in late-stage study.
5 Small Drug Stocks to Buy on Hopes of Better Prospects in the New Year
by Kinjel Shah
Innovation is expected to continue driving growth in the Medical-Drugs industry. DERM, LYRA, AUPH, ALPN and HARP may prove to be good additions to one's portfolio.
Relative Price Strength Makes These 5 Stocks Excellent Buys
by Nilanjan Choudhury
WING, JAKK, NSIT, GIII and DERM are five stocks with explosive relative price strength.
The Zacks Analyst Blog Highlights Beacon Roofing Supply, TopBuild, Journey Medical, and Shift4
by Zacks Equity Research
Beacon Roofing Supply, TopBuild, Journey Medical, and Shift4 are included in this Analyst Blog.
Journey Medical (DERM) Up on Update for Skin Disease Candidate
by Zacks Equity Research
Journey Medical (DERM) plans to submit a new drug application (NDA) to the FDA for DFD-29 to treat rosacea in adults by 2023-end. Stock rises.
4 Growth Stocks to Buy Ahead of a Strong Year-End Rally
by Tirthankar Chakraborty
With the Fed likely to trim interest rates along with seasonal tailwinds, growth stocks like Beacon Roofing Supply (BECN), TopBuild (BLD), Journey Medical (DERM) and Shift4 Payments (FOUR) are poised to gain strength.
Are You Looking for a Top Momentum Pick? Why Journey Medical Corporation (DERM) is a Great Choice
by Zacks Equity Research
Does Journey Medical Corporation (DERM) have what it takes to be a top stock pick for momentum investors? Let's find out.
What Makes Journey Medical Corporation (DERM) a Good Fit for 'Trend Investing'
by Zacks Equity Research
Journey Medical Corporation (DERM) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Is Corvus Pharmaceuticals (CRVS) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Corvus Pharmaceuticals (CRVS) and Journey Medical Corporation (DERM) have performed compared to their sector so far this year.
Journey Medical (DERM) & Maruho Ink Deal for Qbrexza Asia Rights
by Zacks Equity Research
Journey Medical (DERM) enters into a second licensing agreement with Maruho to develop and commercialize Qbrexza to treat hyperhidrosis in certain Asian countries. The stock surges 18.4%.
Journey Medical Corporation (DERM) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Journey Medical Corporation (DERM) delivered earnings and revenue surprises of -35.29% and 15.95%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?